Deucravacitinib
Chemical compound
From Wikipedia, the free encyclopedia
Deucravacitinib, sold under the brand name Sotyktu, is a medication used for the treatment of moderate-to-severe plaque psoriasis.[7] It is a tyrosine kinase 2 (TYK2) inhibitor and it is taken by mouth.[7] It was developed by Bristol Myers Squibb.[10]
| |
| Clinical data | |
|---|---|
| Pronunciation | /duːˌkrævəˈsaɪtɪnɪb/ doo-KRAV-ə-SYE-ti-nib |
| Trade names | Sotyktu |
| Other names | BMS-986165 |
| AHFS/Drugs.com | Monograph |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| Drug class | Tyrosine kinase 2 (TYK2) inhibitor |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 99% |
| Protein binding | 82–90% |
| Metabolism | Liver (primarily CYP1A2) |
| Metabolites | BMT-153261 (active) |
| Elimination half-life | 10 hours |
| Excretion | Feces, urine |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| ECHA InfoCard | 100.329.069 |
| Chemical and physical data | |
| Formula | C20H19D3N8O3 |
| Molar mass | 425.466 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Deucravacitinib was approved for medical use in the United States in September 2022,[7][11][12] and in Australia in December 2022.[1] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[13][14][15]
Medical uses
Mechanism of action
It acts as a highly selective allosteric inhibitor of non-receptor tyrosine-protein kinase 2 (TYK2).[16]
Molecule design
Society and culture
Legal status
In January 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Sotyktu, intended for the treatment of moderate to severe psoriasis.[8][18] The applicant for this medicinal product is Bristol-Myers Squibb Pharma EEIG.[8][18] Deucravacitinib was approved for medical use in the European Union in March 2023.[8]
